Irritable Bowel Syndrome

Screen time ≥2 hours/day at 8 years of age was associated with an increased risk of developing IBD.

The role of psychiatric care may be understated in treating IBD in children and adolescents nearing adult age.

More than half of patients in the mirikizumab arm achieved clinical remission at week 52.

The features of pediatric IBD can be non-specific, but there are signs in biopsies and clinical history that may indicate what is and isn't IBD.

Major advances to biomarkers, targeted therapies and a modernized care team could help IBD specialists achieve a more nuanced care strategy for children.

Findings from the pivotal phase 3 trial that which supported linaclotide's FDA approval show significant benefit in bowel movement and stool consistency.

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

Results from both studies showed the safety of filgotinib for the treatment of ulcerative colitis compared to placebo treatment groups.

Nearly half of patients with IBD in remission experienced abdominal pain, which was associated with sex, fatigue, and depressive symptoms.

The greatest level of treatment discontinuation was seen among patients aged 18-24 years, highlighting an increased risk of early disease relapse.

The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?

Analysis showed a higher proportion of patients with CD with NAFLD, varying across studies and regions.

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

A population-based cohort study highlighted an association between AD and IBD with risk varying by age, AD severity, and subtype of IBD.

Findings from a recent study of patients with IBD on biologic therapy suggest selenium and zinc deficiencies may predict disease outcomes and adverse clinical effects.

Patients receiving systemic corticosteroids faced an increased risk of severe COVID-19 requiring hospitalization or mechanical ventilation compared to other medication classes used to treat IBD.

When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.

The US Food and Drug Administration (FDA) approved linaclotide earlier this month for the treatment of patients with functional constipation aged 6-17 years.

The treatment represents the first approval for pediatric patients with functional constipation.

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.

In addition, 17 female patients who completed PENFS showed improvements in various symptoms, such as pain, disability, and catastrophizing, while carbohydrate degradation and LCFA synthesis pathways decreased in the post-treatment and follow-up analysis.